Competition, page-45

Interesting, I didn't remember that Telix had a deal with Varian and its imaging software previously known as Velocity AI before being acquired from Emory University.

https://ott.emory.edu/about/success/velocity.html

Founded in 2004 at Emory University by radiation oncologists Tim Fox, PhD and Ian Crocker, MD, the Emory start-up company Velocity Medical Solutions produced this new imaging software, Velocity AI™. In March 2014, Varian Medical Systems became the owner of Velocity AI™, after announcing an agreement to acquire Velocity Medical Solutions.

This technology can blend cancer images into one high-quality, 3-D like visual that provides a better look at a tumor's actual boundaries. The software does this by matching soft tissue among multiple image sets through image registration, with deformable image registration, which warps images from different angles and with differing contours together, being one of the product's fundamental driving technologies. Fox relates Velocity AI™ to Doppler radar; like a meteorologist, the physician can use the tool to track changes in the tumor much more effectively.

"Essentially, we're trying to use imaging more as a predictive tool for cancer," he said. "If you're able to assess the tumor response more quickly, then you can modify the treatment if the patient is not responding. It could have a huge impact on patient care."


https://telixpharma.com/wp-content/uploads/20210226_Telix-Annual-Report-2020-FINAL.pdf

Telix entered into a whole range of new partnerships with important companies that will not only help us as we develop new markets and indications for our technology, but also enable us to combine capabilities in ways that have the potential to profoundly affect cancer care. Our partnership with Varian Medical Systems (now a part of Siemens Healthineers) is helping us to understand how advanced prostate cancer imaging may affect traditional radiation oncology. We are exploring ‘next generation’ radiation oncology with RefleXion Medical, one of the most innovative companies in the field. The exciting ‘Imaging and Robotics in Surgery’ or ‘IRiS’ Alliance with Mauna Kea Technologies is one of several important forays into the use of MTR technology in the operating theatre, delivering new tools and techniques to surgeons. We also continued to work closely with key partners such as Cardinal Health, Eckert & Ziegler, PharmaLogic, IRE ELiT, Eczacıbaşı Monrol, JFE Engineering and GE Healthcare, to name but a few. Delivering cancer care is truly a team effort and we are immensely grateful for the commitment and energy that our partners delivered under such challenging conditions.

In September, Telix entered into a strategic collaboration with Palo Alto, California (US) based market leading cancer therapy company Varian Medical Systems, to evaluate the use of advanced prostate cancer imaging within Varian’s radiation treatment planning platform. Telix’s collaboration with Varian aims to utilise Telix’s extensive PSMA PET imaging data, to potentially develop new image-guided treatment planning functions, automated analysis and artificial intelligence capabilities within Varian’s radiation treatment planning platforms.

“Our collaboration with Telix is investigating the potential to incorporate rich diagnostic information into Varian’s bioinformatics and
radiation treatment planning platforms to generate highly personalised and targeted radiation therapy for men with prostate cancer. The additional diagnostic and cancer staging information provided by PSMA PET/CT imaging may offer important insights that impact clinical care decisions for prostate cancer patients.”













https://www.ojs.unito.it/index.php/jbp/article/view/5937

https://www.ojs.unito.it/index.php/jbp/article/view/5937/5183

Adaptive radiation therapy (ART) is an established clinical practice, especially for treatments requiring rapid changes due to organs-at-risk (OAR) that might influence the target position. Adapting the procedure to a case-to-case basis involves combining different tools, such as scanning pretreatment images, clinically assessing the need for adaptation, replanning a new treatment, and guaranteeing the final quality of the entire process. Modern radiation therapy equipment enables multiple optimization strategies, both online and offline.

The primary aim of this study is to define an offline ART procedure to correct the replanning of prostate treatments according to objective evaluation criteria.

The simulation and treatment protocols for prostate patients involve emptying the rectum when needed and ensuring that the bladder is filled with adequate urine volume. To comply with the simulation conditions during the treatment, daily cone-beam computed tomography (CBCT) images are acquired and controlled on a daily basis. The image-guided radiation therapy (IGRT) protocol provides a rigid fusion of the images acquired in the bunker with those collected from the simulation CT. For this study, we selected 23 patients with prostate adenocarcinoma (medium and low risk) treated with 40 fractions, with a daily dose of 2 Gy (80 Gy) at UPMC San Pietro FBF Advanced Radiotherapy Center in Rome, from October 2018 to May 2019.

During the treatment, patients were placed in the supine position, with their arms on their chest and legs restrained by an immobilization device (ProSTEP™ Klarity). The offline ART workflow required pretreatment verifications, registration with the simulation images, and calculation of the rectum and bladder filling variations. The analysis was performed using the Velocity v4.0 software (Varian Medical System, Palo Alto CA). At the end of the Velocity-based software-automated process, the CT and CBCT images were used to generate an aCT (adaptive CT). Organs of interest were contoured on the aCT automatically.

Velocity Bibliography

https://varian.widen.net/s/q8zvmpxvwg/velocity_bibliography_rad10643a_march2021

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333149/

Usefulness of hybrid deformable image registration algorithms in prostate radiation therapy

https://pubmed.ncbi.nlm.nih.gov/32862068/

Margin verification for hypofractionated prostate radiotherapy using a novel dose accumulation workflow and iterative CBCT

https://pubmed.ncbi.nlm.nih.gov/31755658/

Structure guided deformable image registration for treatment planning CT and post stereotactic body radiation therapy (SBRT) Primovist ® (Gd-EOB-DTPA) enhanced MRI

https://pubmed.ncbi.nlm.nih.gov/27511856/

Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial